Toggle Dropdown
Groups
Announcements
Projects
News & Events
Welcome guest
Log in
Friends
Loading
Loading...
https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional
0
0
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease | Eli Lilly and Company - Investors | Eli Lilly and Company
5/3/23 at 3:01am
Organization
Lilly.com
47 words
0
Comments
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
general
Business Finance
Donanemab Significantly Slowed Cognitive
Eli Lilly
Functional Decline
Alzheimer's
The Investor Relations
You are the first to view
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...